Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.

Antiviral research - 1 Aug 2003

Mo Hongmei, Lu Liangjun, Dekhtyar Tatyana, Stewart Kent D, Sun Eugene, Kempf Dale J, Molla Akhteruzzaman

Abstract excerpt

Lopinavir (LPV, formerly ABT-378) is an HIV protease inhibitor (PI) that is co-administered with a small amount of ritonavir (RTV), which greatly increases and sustains the plasma levels of LPV. Lopinavir/ritonavir (LPV/r) has shown potent antiviral activity in both therapy-nai;ve and PI-experien...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV-1
Share to HIV Protease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Pyrimidinones

Share to Ritonavir

Share to Serial Passage

Source

Identifiers

PMID: 12927307
DOI: 10.1016/s0166-3542(03)00107-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12927307-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.PMID 12927307Read ↗

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.Semantic proximity Read ↗

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.Semantic proximity Read ↗

Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments.Semantic proximity Read ↗

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.Semantic proximity Read ↗

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.Semantic proximity Read ↗

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.Semantic proximity Read ↗

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.Semantic proximity Read ↗

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.Semantic proximity Read ↗

Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.Semantic proximity Read ↗

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks.Semantic proximity Read ↗

In vitro selection and characterization of human immunodeficiency virus type 1 resistant to Zidovudine and tenofovir.Semantic proximity Read ↗

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.